No causative genes are listed for primary peritoneal carcinoma in this packet, and no inheritance pattern is certified, so the genetic basis is not described here. The packet definition places the origin of the tumor in the peritoneum, with a microscopic appearance resembling surface epithelial-stromal tumors of the ovary.

The packet definition states that the diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement. Other diagnostic methods are not certified in this packet. Newborn screening is not listed.

The packet lists two FDA-approved products with active market status that are linked to this condition. Olaparib (Lynparza) is a small-molecule drug approved through a New Drug Application reviewed by the FDA Center for Drug Evaluation and Research, with an approval date of 2017-08-17. Bevacizumab (Avastin) is a biologic approved through a Biologics License Application, with an approval date of 2004-02-26. FDA orphan-drug records in the packet list each of these for treatment of primary peritoneal cancer. The same orphan-drug records include other products with DESIGNATED status, which is a development-stage designation and not an approval, and two products with WITHDRAWN status. Foundational therapies and expert-review management guidance are not certified in this packet, so other treatment approaches are not described here. Patient assistance programs may exist for some approved medicines; details are not provided in this packet.

Prognosis is not certified in this packet. No natural history or survival information is available here, and none is inferred. Outcomes in cancers generally vary between individuals.

ClinicalTrials.gov records in the packet indicate that studies involving this condition are currently active. The packet lists examples drawn from trials that enroll people with ovarian, fallopian tube or primary peritoneal cancers. NCT05554328 is a Phase 2 National Cancer Institute trial of targeted treatment for recurrent or persistent ovarian and endometrial cancers with RAS pathway mutations, with status active, not recruiting, and a start date of 2023-04-25. NCT06824467 is a Phase 3 Merck Sharp & Dohme study of maintenance treatment in platinum-sensitive recurrent ovarian cancer, with status recruiting and a start date of 2025-04-09. NCT03587311 is a Phase 2 National Cancer Institute trial in refractory ovarian, fallopian tube or primary peritoneal cancer, with status active, not recruiting. Trial listings change over time, and the ClinicalTrials.gov search page provides current records.